Enzymatic production of d-allulose as a low-calorie functional sugar for healthy weight management

Overview

D-allulose is a functional, low-calorie sugar that delivers the taste and functionality of sucrose with approximately 90% fewer calories and minimal impact on blood glucose and insulin. Beyond calorie reduction, scientific evidence points to benefits in fat metabolism, energy balance, and reduced body-fat accumulation, positioning allulose as a promising ingredient for healthy-weight and metabolic-health applications across food products, including wet food, dry food, and treats.

Ambrosia Bio's proprietary enzymatic technology enables cost-efficient, scalable production of D-allulose, overcoming the cost and scale barriers that have historically limited broad market adoption of this rare sugar. The platform converts common sugars into high-value, low-calorie sweeteners, allowing manufacturers to reduce sugar content while preserving taste, texture, and sensory experience.

Technical specifications

Production platform:

• Proprietary enzyme-based biocatalysis converts common sugars and feedstocks, such as sucrose, into rare low-calorie sugars including D-allulose
• Plug-and-play bioprocess integrates into existing sugar refinery and starch processing infrastructure with minimal operational modification
• Synthetic enzymes are engineered for high stability and catalytic activity, enabling cost-effective production at scale

Functional benefits:

• Sugar-like taste, mouthfeel, and processing functionality across multiple food formats
• Approximately 90% fewer calories than sucrose
• Minimal glycemic and insulinemic response
• Supported by human clinical studies demonstrating reduced body-fat mass, reduced body-fat percentage, and increased post-meal fat oxidation
• Animal studies indicate beneficial effects on lipid metabolism, energy expenditure, and appetite-related pathways

Technology readiness level

The technology is at an early stage of development, with the production platform established and the functional-benefit hypothesis supported by existing clinical and animal literature. A structured four-stage validation program is planned: formulation and stability testing of D-allulose in selected wet, dry, and treat formats under relevant processing and shelf-life conditions; palatability and gastrointestinal tolerance assessment; controlled studies evaluating food intake, body weight, fat mass, lean mass, and metabolic markers; and optimization of dose and formulation followed by scale-up and regulatory assessment toward commercial implementation.